Non-sedation versus sedation with a daily wake-up trial in critically ill patients receiving mechanical ventilation—effects on physical function: study protocol for a randomized controlled trial: a substudy of the NONSEDA trial by Helene Korvenius Nedergaard et al.
TRIALS
Nedergaard et al. Trials  (2015) 16:310 
DOI 10.1186/s13063-015-0856-1STUDY PROTOCOL Open AccessNon-sedation versus sedation with a daily
wake-up trial in critically ill patients receiving
mechanical ventilation—effects on physical
function: study protocol for a randomized
controlled trial: a substudy of the NONSEDA trial
Helene Korvenius Nedergaard1*, Hanne Irene Jensen1, Jørgen T. Lauridsen2, Gisela Sjøgaard3 and Palle Toft4Abstract
Background: Critically ill patients rapidly loose much of their muscle mass and strength. This can be attributed to
prolonged admission, prolonged mechanical ventilation and increased mortality, and it can have a negative impact on
the degree of independence and quality of life. In the NONSEDA trial we randomize critically ill patients to non-sedation
or sedation with a daily wake-up trial during mechanical ventilation in the intensive care unit. It has never been assessed
whether non-sedation affects physical function. The aim of this study is to assess the effects of non-sedation versus
sedation with a daily wake-up trial on physical function after discharge from intensive care unit.
Methods/Design: Investigator-initiated, randomized, clinical, parallel-group, superiority trial, including 700 patients
in total, with a substudy concerning 200 of these patients. Inclusion criteria will be intubated, mechanically ventilated
patients with expected duration of mechanical ventilation >24 h. Exclusion criteria will be patients with severe head
trauma, coma at admission or status epilepticus, patients treated with therapeutic hypothermia, patients with PaO2/
FiO2<9 where sedation might be necessary to ensure sufficient oxygenation or placing the patient in a prone position.
The experimental intervention will be non-sedation supplemented with pain management during mechanical
ventilation. The control intervention will be sedation with a daily wake-up trial. The co-primary outcome will be
quality of life regarding physical function (SF-36, physical component) and degree of independence in activities of daily
living (Barthel Index), and this will be assessed for all 700 patients participating in the NONSEDA trial. The secondary
outcomes, which will be assessed for the subpopulation of 200 NONSEDA patients in the trial site, Kolding, will be
6-min walking distance, handgrip strength, muscle size (ultrasonographic measurement of the rectus femoris muscle
cross-sectional area) and biomechanical data on lower extremity function (maximal voluntary contraction, rate of force
development and endurance).
Discussion: This study is the first to investigate the effect of no sedation during critical illness on physical function. If
an effect is found, it will add important information on how to prevent muscle weakness following critical illness.
Trial registration: The study has been approved by the relevant scientific ethics committee and is registered at
ClinicalTrials.gov (ID: NCT02034942, 9 January 2014).
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This trial is a substudy in the NONSEDA trial (Clinical
Trial identifier: NCT01967680). The aim of the NON-
SEDA trial is to assess the benefits and harms of non-
sedation versus sedation with a daily wake-up trial in
critically ill patients in the intensive care unit (ICU). The
NONSEDA trial is a multinational trial, where 700
patients will be randomized to non-sedation versus
sedation with a daily wake-up trial.
Two hundred of the 700 patients in the NONSEDA
trial will be included, treated and followed up in the in-
tensive care unit in Kolding. This protocol describes a
substudy concerning physical function (quality of life re-
garding physical function, walking ability, ability to per-
form everyday tasks, biomechanical data and muscle
size) and will be based on these 200 patients.
Patient population
In Denmark approximately 30,000 patients (2-3 % of all
hospital patients) are admitted to ICUs every year. In 2011
mortality during the ICU stay was 12.7 % and 30-day
mortality 21.2 % [1]. An intensive care admission can have
substantial consequences for patients, and studies showFig. 1 Flowchart. Schematic presentation of the patient flow through the tthat ICU survivors have a decreased quality of life and
increased mortality for years after discharge [2].
Current care and treatment
Muscle wasting and ICU-acquired weakness is frequently
encountered in the ICU, affecting up to 25 % of patients
requiring mechanical ventilation for more than a week
and more than half of the patients suffering from severe
sepsis [3, 4]. Muscle mass reduces rapidly, with severely
septic patients losing 15-20 % within the first week [3]. It
is a condition with high costs for both the patient and the
healthcare system, since it is associated with increased
length of stay in the ICU and hospital, prolonged mechan-
ical ventilation and increased in-hospital mortality, and it
affected the quality of life for months or even years after
discharge [2, 3, 5–7].
Since the dawn of ventilator therapy, it has been standard
care to sedate the patients continuously. The first ventila-
tors were rather primitive and very uncomfortable for the
patients, making the sedation practice necessary. As ventila-
tors have become increasingly advanced, and now allow for
high patient-ventilator interaction and relative comfort, the
focus has been on a lighter level of sedation. Numerousrial
Fig. 2 Ultrasonographic measurement of the rectus femoris muscle cross-sectional area. The rectus femoris muscle is part of the quadriceps muscle.
Patients will be placed in supine position with their back raised to 45 degrees, with their legs in passive extension. The transducer will be placed over the
rectus femoris muscle, perpendicular to the long axis of the right thigh, not depressing the dermal surface. Measurements will be made at 2/3 of the
distance from the anterior superior iliac spine to the superior patellar border. This distance will be defined when the patient is placed as noted above, not
with the patient standing up, since this changes the distance. For the scan, a linear transducer will be used, flat footprint, 5–8 MHz. The muscle is identified
visually and an ultrasonographic picture is taken. Using the ultrasonographic software, the outer edge of the muscle is marked, and the cross-sectional area
is calculated using planimetry
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namely shorter duration of mechanical ventilation, lower
morbidity and shorter length of stay in the ICU and hos-
pital [8–14]. Ali and colleagues have demonstrated an
association between the time patients spend in coma
and muscle wasting and ICU-acquired weakness [7, 15].
Schweikert and colleagues carried out a randomized,
clinical trial of sedation interruptions combined with
early physiotherapy for mechanically ventilated, critic-
ally ill patients [16]. Their intervention group had more
ventilator-free days and a better functional outcome at
hospital discharge. Several trials have demonstrated
that it is both feasible and safe to mobilize mechanically
ventilated ICU patients [17].
It is appealing to speculate that less sedation will
lead to more alert and thereby more physically active
patients, who can be mobilized to a larger extent [18].
However, it has not been established whether physical
function following ICU discharge is affected by non-
sedation versus the standard care of sedation with a
daily wake-up trail.
In the NONSEDA trial protocol we did at systematic
literature search, which established that, for the present
(October 2014), only one randomized clinical trial on the
effect of non-sedation versus sedation with a daily wake-
up trial has been published, namely the aforementioned
trial from Odense University Hospital [9]. This trial did
not investigate physical function.Trial conduct
The protocol has been approved by The Regional Scientific
Ethical Committees for Southern Denmark (protocol ID: S-
20130025). We will obtain informed consent from the pa-
tients who are sufficiently awake; otherwise, the informed
consent will be obtained from the closest relative and the
patient’s general practitioner, alternatively the Medical
Health Office.
The trial is registered at ClinicalTrials.gov, ID: NCT0203
4942 (9 January 2014).
The trial has been approved by the Data Protection
Agency (#2008-58-0035, approval for the Region of South-
ern Denmark).
Trial objective
The objective will be to assess the benefits and harms
of non-sedation versus sedation with a daily wake-up
trial in critically ill patients concerning physical func-
tion following ICU-discharge.
Trial hypothesis
The primary hypothesis is that non-sedation compared
with sedation and a daily wake-up trial will lead to less
affected physical function following ICU discharge.
Design
The trial is a substudy in the NONSEDA trial (Clini-
calTrial ID: NCT01967680). The NONSEDA trial is an
Fig. 3 Study setup for biomechanical measurements of the lower limbs. 1: Custom-made chair, where the participant will be seated, back straight, with 90
degree flexion in the hip, 90 degree flexion in the knee, to ensure that the lower leg is in a vertical position. A safety strap will be fastened at the hip and
hands held in the lap. 2: A strap will be fastened around the ankle, ensuring that the rigid transducer arm (3) is horizontal. 3: Strain-gauge transducer. 4:
Computer with software for data collection. 5: Screen, where the participant will get visual feedback during endurance testing. A line will be marked on the
screen (6), representing 25 % of the participants’ maximal voluntary contraction (MVC). Made with inspiration from J.B. Poulsen and colleagues [47]. The
following measurements will be performed: the maximal voluntary contraction (MVC) and rate of force development (RFD). The participant is carefully
instructed, using the same wording every time, to “stretch your leg as forcefully and as quickly as possible.” When maximal tension has been reached, it is
maintained for 1–2 s and then released. The peak of the force-time curve is the MVC. The steepest slope of the curve is the RFD. Endurance: 25 % of the
participants’ MVC will be calculated, and a line will be depicted on the screen. The participant will be instructed to exert a force sufficient to reach the line,
not more, not less. The participant will maintain this force for as long as possible, though maximally 3 min. The participant will have constant visual
feedback and standardized verbal encouragement, if needed
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multinational, superiority trial designed to include 700 pa-
tients from at least six intensive care units in Denmark,
Norway and Sweden. Two hundred of the 700 patients
will be included, treated and followed up in the ICU in
Kolding. This substudy will be based on these 200 patients
(see section “Outcomes”) Fig 1.
Randomization
Patients will be randomized to one of the two groups
within 24 h after intubation. If the patient arrives intu-
bated from another ICU, the patient will be randomized
within the first 24 h after arrival. The randomization will
be carried out centrally by the Copenhagen Trial Unit
according to a computer-generated allocation sequence
with a variable block size, kept concealed from the inves-
tigators at the clinical sites. The allocation sequence will
be stratified by center, age (up to 65 years or older) and
shock at admission (systolic blood pressure <70 mmHg
or above). The 200 patients for this substudy will be all
the patients included in the Kolding trail site. Since we
will stratify for center, we will obtain an equal distri-
bution of the patients. The randomization system will
be Internet based with 24 h access a day, 7 days a
week. The participant allocation will be carried out byan investigator who logs in to the CTU’s Online
Randomization System using a personal ID and PIN
code. Then the investigator will type in all relevant in-
formation about the participant, and the participant
will be subsequently allocated to either the ‘non-sed-
ation group’ or the ‘sedation group.’Blinding
Due to the nature of the trial interventions, it will not
be possible to blind the investigators at clinical trial
sites, the participants or the participants’ relatives. All
other parties in the trial will be blinded. The statistical
analyses will be conducted blinded with the two inter-
vention groups coded as, e.g., A and B.
Concerning the two co-primary outcomes in this sub-
study (the SF-36 and Barthel Index), all information
about the questionnaire will be standardized and similar
for all participants, and the research assistant handling
the data will be unaware of the patient’s treatment allo-
cation. If, in rare circumstances, it is necessary to per-
form the questionnaires as a telephone interview, this
will be done by an investigator from another trial site
than where the patient was treated; the assessor will thus
be blinded.
Fig. 4 Outcomes and time points. The primary, secondary and exploratory outcomes and relevant time points
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 Endotracheally intubated
 Expected time on ventilator >24 h
 Age ≥18 years
 Informed consent
Exclusion criteria
 Severe head trauma where therapeutic coma is
indicated
 Therapeutic hypothermia where therapeutic coma is
indicated
 Status epilepticus where therapeutic coma is
indicated
 The patient has participated in the study before
 The patient was transferred from another ICU with
length of stay >48 h
 The patient is comatose at admission
 PaO2/FiO2 ≤ 9, where sedation might be necessary
for oxygenationTrial site and personnel
The Intensive Care Unit, Lillebaelt Hospital, Kolding, is
a mixed medical and surgical ICU with 11 ICU beds and
3 intermediate care beds. The unit treated 850 patients
in 2012 and 894 patients in 2013. The trial personnel
will be doctors, nurses and physiotherapists working in
the Kolding ICU. The personnel are already used to
working with non-sedation and handling awake, mech-
anically ventilated patients as well as sedated patients
with daily wake-up trials. The trial group will monitor
the clinical work and, if needed, provide supplementary
training in non-sedation and daily wake-up trials, both
in theory and by supervised practice.Interventions
As described in the NONSEDA trial protocol, the interven-
tion consists of non-sedation versus sedation with a daily
wake-up trial. In this substudy we will investigate how non-
sedation versus sedation with a daily wake-up trial affects
physical function after ICU discharge. For details about the
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Trial identifier NCT01967680 (www.clinicaltrials.gov).
Co-interventions
As stated in the NONSEDA trial protocol, both groups
will receive analgesic treatment as usual, with opiates
and paracetamol, in order to keep patients comfortable.
In case the patient arrives at the department with an epi-
dural catheter, the analgesia will continue via the epi-
dural catheter as usual. The Numeric Rating Scale (NRS,
0–10) will be used to monitor the need for supplemental
analgesics, and morphine will be given if the NRS is ≥ 3
at rest and ≥5 during activity.
Mobilization and physical activation of the patients are
not done according to a protocol, but are carried out in
accordance with the local standards of the Kolding ICU.
We will register the amount of passive and active
mobilization for each patient on a daily basis, since one
can speculate that the more awake a patient is, the more
they will be mobilized.
We have defined three co-interventions, which are
suspected of being associated with the development of
ICU-acquired weakness, although the results of trials
have been contradictory [5, 19–21]. They will be regis-
tered and presented for each intervention group:
 Use of neuromuscular blocking agents
 Use of corticosteroids
 Blood glucose profiles
The co-interventions defined in the NONSEDA trial
protocol are use of vasoactive agents and antibiotics as well
as total amount of fluids given. These co-interventions are
not thought to have a direct effect on muscular function,
which is why we have defined separate co-interventions for
this substudy.
Outcomes
Outcomes on physical function will be investigated for
the two different patient populations separately, namely
the total population of all 700 patients in the NONSEDA
trial and the 200 patients in the substudy from the Kold-
ing trial site. The primary outcome of this substudy will
be based on the total population of 700 patients and will
be a co-primary outcome of:
 patient-reported quality of life, as measured by SF-
36v2, physical component score [22, 23] and degree
of independence in activities of daily living, as mea-
sured by the Barthel Index [24–26].
The secondary outcomes of this substudy will be based
on the subpopulation of 200 patients participating in the
substudy in Kolding and will be: Walking distance in the 6-min walk test at 3-month
follow-up [27–32]
 Handgrip strength at 3-month follow-up [7, 33–35]
 Barthel Index at discharge from the ICU
 Muscle size, measured as cross-sectional area of the
rectus femoris muscle (see Fig. 2) at 3-month
follow-up [36]
 Muscle strength, measured using biomechanical
measurements−maximal voluntary contraction
(MVC), rate of force development (RFD) and
endurance at 25 % of the MVC (see Fig. 3) at 3-
month follow-up [37–40].
Exploratory outcomes will be:
 Handgrip strength at extubation
 Handgrip strength at ICU discharge
 Muscle size, measured as cross-sectional area of the
rectus femoris muscle, at extubation
 Muscle size, measured as cross-sectional area of the
rectus femoris muscle, at ICU discharge Figs. 2, 3
and 4.
Safety
There is no known risk associated with participation in the
substudy. As a part of the NONSEDA protocol we register
accidental extubation requiring re-intubation within an
hour and accidental removal of the central venous line
requiring reinsertion within 4 h as serious adverse events.
Inclusion of patients
Patients can be admitted to the ICU either from the same
hospital (emergency department or another ward) or trans-
ferred from an ICU in another hospital. If they are admitted
from within the same hospital, they are either not intubated
or have been intubated within a very short time, for ex-
ample during pre-hospital care. Patients will be included in
the study within 24 h from intubation.
Patients transferred from an ICU in another hospital are
very often intubated. If they are transferred from another
ICU, they can be included in the trial if the stay in the other
ICU was shorter than 48 h. In the time leading up to inclu-
sion and randomization, it will vary whether patients are se-
dated or not, depending on the particular clinician on duty
and traditions at the particular hospital.
Obtaining informed consent
When patients are contacted the first time concerning par-
ticipation in the study, they will be at the ICU. Verbal and
written information will be given by one of the participating
physicians or study nurse. Patients are informed about the
rights to assistance and the possibility of reflection time. Pa-
tients will be considered competent if they are awake and
not delirious (negative CAM-ICU). The competent patients
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several hours. If patients are not awake and not competent
because of their illness, surrogate consent will be obtained
from a close relative and the patient’s private practitioner,
alternatively the Medical Health Office. The consent of a
relative relies on the patient’s presumed attitude to partici-
pation in clinical trials. The connection between the relative
and the patient will appear in the surrogate consent form.
Like the patient, the relative is also given time of up to sev-
eral hours to make the decision.
If a patient or the relatives no longer wish to partici-
pate in the trial for any reason, they will be asked for
permission to use the already obtained data, to obtain
data from electronic patient files for the rest of the trial
period and to invite the patient to the 90-day follow-up.Data collection
The table in Fig. 4 shows the types of data and the time
the data will be collected. If not otherwise stated, data ori-
ginate from medical records included in the Critical Infor-
mation System (CIS) or other electronic patient files.
The SF 36v2 questionnaire and the Barthel Index will be
sent to the participant, who will fill it out at home and
bring it to the follow-up. If a participant has not filled out
the questionnaire before the follow-up, the participant will
be asked to complete the questionnaire at follow-up. They
will be seated in privacy in a calm place, with sufficient
time to fill out both questionnaires (at least 30 min).
In an effort to minimize missing data as much as
possible, both the SF-36v2 and Barthel Index can be
performed as a telephone interview. Telephone interviews
are a last resort, and every effort will be made to ensure
that as many patients as at all possible fill out the ques-
tionnaires themselves. SF-36 can only be carried out as an
interview with the participant in person, since it concerns
the person’s self-perceived quality of life. The Barthel
Index is preferably performed as an interview with the
participant in person, but if no other option exists, it can
be carried out with a proxy instead. Therefore, if a partici-
pant for some reason is unable to participate in the
follow-up and unable to fill out the questionnaire, a tele-
phone interview will be performed. It is estimated that a
telephone interview will take approximately 20 min.
Measurements of muscle size and biomechanical data
will be obtained by investigator HKJ and a trial nurse. If
the participant is not able to come to the hospital for
follow-up, we will ask if we can come to their home to do
the follow-up. The 6-min walk test can be performed on
an outdoor, marked 30-m trail at the participant’s home if
they are able to walk. Ultrasonographic measurements of
muscle size can likewise be performed at the participant’s
home. Biomechanical data can only be collected in the
hospital because the equipment is very difficult to move.Before contacting any patient after discharge, we will
check with national central person registrations to as-
sure that the patient is not deceased. In summary, the
process for establishing the follow-up will be as follows:
Approximately 14 days prior to the 3-month follow-up
we will send a letter to the patient, containing the invita-
tion to the follow-up and the questionnaires to be filled
out (SF-36 and Barthel Index). If the patient does not re-
spond within 10 days, we will phone the patient. We will
first repeat the invitation to participate in the follow-up
and clarify any misunderstandings concerning payment
for transportation or the like. If the patient declines to
come to the hospital, we will offer to come to the pa-
tient’s home and do the follow-up there (6-min walk test
and muscle size). If the patient declines this, we will ask
if we can perform the SF-36 and Barthel Index over the
telephone.
Data management
An electronic Case Record Form (eCRF) for the NON-
SEDA trial in Open Clinica is developed in cooperation be-
tween the coordinating investigator and a data manager at
Copenhagen Trial Unit. Access to the eCRF will be possible
around the clock every day where data continuously can be
entered for all the randomized patients.
The coordinating investigator will have access to monitor
the data input. If the entry is partially or completely missing
or seems flawed on one or more randomized patients, the
coordinator will have the opportunity to contact the pri-
mary investigator in order to correct or complement data
inputs to optimize the quality of the data.
Power estimation
The sample size estimation for the NONSEDA study
will be 700 patients, with 350 in each group [please
see the NONSEDA trial protocol, Clinical Trial identi-
fier NCT01967680 (www.clinicaltrials.gov) for details].
These sample size calculations were made using the
power and sample size program PS [41].
Estimation of power for the co-primary outcome: We will
have a sample of 350 experimental participants and 350
control participants. Based on similar study populations, we
estimate 40 % mortality [42, 43]. The study population for
co-primary outcome analyses will therefore be a total of
420 patients, with 210 in each group. Although every effort
will be made to obtain as high a response rate as at all pos-
sible, we have to expect some degree of non-responders,
which we estimate will be 10 %. That leaves 378 patients,
189 in each group.
 SF-36, physical component score: We expect that
the response within each subject group is normally
distributed with a standard deviation of 20 and a
minimal clinically relevant difference of 5 [44]. Since
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sedation on physical function, it is unknown how
large an effect can be expected. If the true difference
in the experimental and control means is 5, we will be
able to reject the null hypothesis that the population
means of the experimental and control groups are
equal with a probability (power) of 0.57. If the true
difference is 7, we will be able to reject the null
hypothesis with a probability (power) of 0.87. The
type I error probability associated with this test of this
null hypothesis is 0.025.
 Barthel Index: We expect that the response within
each subject group is normally distributed with a
standard deviation of 5 and a minimal clinically
relevant difference of 2 [45]. If the true difference in
the experimental and control means is 2, we will be
able to reject the null hypothesis that the population
means of the experimental and control groups are
equal with a probability (power) of 0.95. The type I
error probability associated with this test of this null
hypothesis is 0.025.
Estimation of the power for the main secondary out-
come: We will have a sample of 100 participants and
100 control participants. We estimate 40 % mortality.
The study population for the main secondary outcome
will therefore be a total of 120 patients with 60 in each
group. Since this group of patients is fragile and often
elderly, and since participation in the follow-p requires
an hour of active participation and (most often) a trip to
the hospital, we estimate that 25 % will not participate
in the follow-up, leaving 90 patients, 45 in each group.
 Six-minute walk test: We expect that the response
within each subject group is normally distributed
with a standard deviation of 90 [31] and a minimally
clinically relevant difference of 55 m [30]. If the true
difference in the experimental and control means is
55, we will be able to reject the null hypothesis that
the population means of the experimental and
control groups are equal with a probability (power)
of 0.82. The type I error probability associated with
this test of this null hypothesis is 0.05.Statistical analysis plan
All continuous normally distributed outcome data will be
described by the mean, mean difference, standard deviation
(SD) and range. Non-normally distributed outcome data
will be described by the median and interquartile range.
Student’s t-test and multiple regression will be used to
analyze the differences between the two groups. For non-
normally distributed data non-parametric analyses such as
the Mann-Whitney U-test will be used. Multiple regressionwill be used to handle repeated measurements. We will per-
form intention-to-treat analyses.
All patients are followed up for at least 3 months after
discharge via the electronic eCRF, Social Security Regis-
ter and the National Patient Register. Missing data will
be handled in accordance with multiple imputation pro-
cedures if missing data are greater than 5 % and Little’s
test is statistically significant [46]. The imputation result
will be considered the primary overall result but per
protocol analyses will also be presented.
All raw p-values and confidence intervals of all out-
come comparisons between the two groups will be
presented. A p-value < 0.05 will be considered statisti-
cally significant in all analyses, except for co-primary
outcome, where a p-value < 0.025 will be considered
statistically significant. Statistical analysis of the data
will be done using STATA 13.
Discussion
The purpose of this randomized controlled trial is to
investigate whether the degree of sedation during venti-
lator treatment affects physical function after discharge
from the ICU, with self-perceived quality of life concern-
ing the physical function and degree of independence in
every activity as primary outcome.
The literature on how non-sedation affects physical
function is very limited, since the tradition as well as
current golden standard is a higher degree of sedation,
although, for the time being, there is a growing interest
in limiting sedation and applying early mobilization and
physiotherapy in the ICU. Having non-sedated patients
on the ventilator seems to increase the amount of phys-
ical activity not only during formal physiotherapy ses-
sions, but also for the rest of the days, where the patient
is able to move around in a bed or chair to a greater ex-
tent. Whether this plays a role in the physical status
after discharge is unknown.
Since this trial is a part of a larger trial, where sedation
with a daily wake-up call versus non-sedation is the inter-
vention, there is no separate intervention concerning phys-
ical function. Since it is obvious to speculate that the non-
sedated patients will be mobilized to a larger extent, we will
quantify the degree of physical activity every day, both ac-
tive (e.g., standing on the floor, bed-biking) and passive
(e.g., passive movements of the limbs by the physiotherap-
ist). However, all the small movements a non-sedated pa-
tient might make during the day cannot be quantified.
Taking other possible confounders into concern, e.g., blood
sugar, use of neuromuscular blocking agents or steroids,
this might be part of the explanation if non-sedated patients
prove to have a better physical status. These factors will
also be quantified.
ICU survivors are a group of mainly elderly patients
with a high degree of comorbidity. This complicates the
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weak to participate. As secondary and exploratory out-
comes, we try to obtain data on physical function already
at the time of extubation and at ICU discharge. This might
prove to be futile, since patients at these time points are
far from recovered. With two pilot patients we attempted
to obtain biomechanical data on lower limb function at
ICU discharge, but we had to realize that the patients at
this time point are not in a condition where this is pos-
sible. In an attempt to obtain early data that are not de-
pending on patient cooperation, we measure the muscle
size of the rectus femoris muscle and thereby quantify the
amount of muscle wasting in the two groups. What could
complicate these measurements is the degree of edema,
which ICU patients (especially septic patients) are prone
to. It does seem reasonable to assume that the degree of
edema will be equal between the two groups at the time
of inclusion and at the time of extubation and discharge.
We are also aware that the mere size of a muscle does not
in itself translate to function, and muscle size must be
regarded as a surrogate parameter.
Poulsen and colleagues in 2013 published results on
biomechanical function in ICU survivors (males, aged
50–75 years, 12 months after ICU discharge) compared
to healthy, age- and sex-matched controls [47]. Their
study is the first to provide data on biomechanical data
in ICU survivors and, to the best of our knowledge, still
the only one. Our setup is in many respects similar to
theirs, hopefully providing the basis for comparisons.
Among others, Poulsen et al. found that especially the
rate of force development was negatively affected in ICU
survivors. The rate of force development is known to be
an important factor in activities of daily living since it is
crucial for postural stability. The rate of force develop-
ment can be improved with specific training programs.
Should our study support this finding or reveal other
characteristics of muscles recovering after critical illness,
it could provide further basis for targeted physiotherapy
interventions.
>The validity of this trial is affected by the fact that it
is not blinded, but blinding is not possible with this
intervention. We find that the very realistic clinical context
the trial is set in—broad inclusion criteria, mixed ICU and
numerous caregivers—increases its generalizability and ex-
ternal validity.
We find that the use of sedatives for critically ill patients
is still affected by tradition and habits, and it varies from
department to department. With the NONSEDA trial we
hope to shed light on the possible benefits or harms of be-
ing non-sedated. Non-sedation is a complex intervention
and has numerous possible consequences, and all of these
deserve to be clarified in order to obtain a nuanced picture
of whether non-sedation is the way forward. One of these
possible consequences is the effect on physical function.Trial status
The trial is now actively recruiting patients. We have in-
cluded 96 of the 200 patients (July 2015).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HKN carries out the inclusion of patients, quality control of the intervention
from day to day and follow-up investigation and drafted the manuscript.
HIJ participated in the design of the study and the statistical analysis plan.
JTL participated in the design of the study and the statistical analysis plan.
GS participated in the design of the study and provided biomechanical
measurement equipment and training in its use. PT conceived the study
and participated in its design and coordination (including financing) and
helped to draft the manuscript. All authors reviewed the manuscript and
approved the final manuscript.
Authors’ information
Sponsor and principal supervisor: Palle Toft, MD, Professor, DMSc,
Department of Anesthesiology and Intensive Care, Odense University
Hospital.
Primary investigator, PhD student: Helene Korvenius Nedergaard, MD,
Department of Anesthesiology and Intensive Care, Lillebaelt Hospital,
Kolding.
Co-supervisor: Hanne Irene Jensen, post-doctoral student, Department of
Anesthesiology and Intensive Care, Lillebaelt Hospital, Kolding.
Co-supervisor: Jørgen T. Lauridsen, Professor.
Co-supervisor: Gisela Sjøgaard, Professor and Head of the Research Unit,
Department of Sports Science and Clinical Biomechanics, University of
Southern Denmark.
Acknowledgement
An investigator-initiated, randomized, clinical, parallel-group, multinational,
superiority trial.
Finance
The NONSEDA-trial is funded by the Danish Strategic Research Council, The
Danielsen Foundation and The Scandinavian Society of Anaesthesiology and
Intensive Care.
The custom-built chair for the biomechanical measurements and device for
measuring handgrip strength are provided by the Department of Sports
Science and Clinical Biomechanics, University of Southern Denmark.
Timetable
Inclusion of the first patient 1 September 2014; inclusion of the last patient 1
January 2017
Author details
1Department of Anesthesiology and Intensive Care, Lillebaelt Hospital,
Skovvangen 2-8, DK-6000 Kolding, Denmark. 2Department of Business and
Economics, Centre of Health Economics research, University of Southern
Denmark, Campusvej 55, DK-5230 Odense M, Denmark. 3Department of
Sports Science and Clinical Biomechanics, University of Southern Denmark,
Campusvej 55, DK-5230 Odense M, Denmark. 4Department of Anesthesiology
and Intensive Care, Odense University Hospital, Sdr. Boulevard 29, DK-5000
Odense C, Denmark.
Received: 17 April 2015 Accepted: 9 July 2015
References
1. Danish Intensive Care Database, DID. [in Danish] Available at: https://
www.sundhed.dk/content/cms/12/4712_aarsrapport-2011-did-290612.pdf.
Accessed September 10, 2013.
2. Granja C, Amaro A, Dias C, Costa-Pereira A. Outcome of ICU survivors: a
comprehensive review. The role of patient-reported outcome studies. Acta
Anaesthesiol Scand. 2012;56:1092–103.
3. Parry SM, Berney S, Koopman R, Bryant A, El-Ansary D, Puthucheary Z, et al.
Early rehabilitation in critical care (eRiCC): functional electrical stimulation
Nedergaard et al. Trials  (2015) 16:310 Page 10 of 10with cycling protocol for a randomised controlled trial. BMJ Open. 2012;2,
e001891.
4. Gerovasili V, Stefanidis K, Vitzilaios K, Karatzanos E, Politis P, Koroneos A,
et al. Electrical muscle stimulation preserves the muscle mass of critically ill
patients: a randomized study. Crit Care. 2009;13:R161.
5. Schefold J, Bierbrauer J, Weber-Carstens S. Intensive care unit-acquired
weakness (ICUAW) and muscle wasting in critically ill patients with severe
sepsis and septic shock. J Cachex Sarcopenia Muscle. 2010;1:147–57.
6. Herridge MS, Cheung AM, Matte-Martyn TC, Diaz-Granados N, Al-Saidi F,
Cooper AB, et al. One-year outcomes in survivors of the acute respiratory
distress syndrome. N Engl J Med. 2003;348:683–93.
7. Ali NA, O’Brien JM, Hoffmann SP, Phillips G, Garland A, Finley JC, et al.
Acquired weakness, handgrip strength, and mortality in critically ill patients.
Am J Respir Crit Care Med. 2008;178:261–8.
8. Olofsson K, Alling C, Lundberg D, Malmros C. Abolished circadian rhythm of
melatonin secretion in sedated and artificially ventilated intensive care
patients. Acta Anaesthesiol Scand. 2004;48:679–85.
9. Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill
patients receiving mechanical ventilation: a randomised trial. Lancet.
2010;375:475–80.
10. Kollef M, Levy N, Ahrens T, Schaiff R, Prentice D, Sherman G. Use of
continuous iv sedation is associated with prolongation of mechanical
ventilation. Chest. 1998;114:541–8.
11. Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, et al.
Effect of a nursing-implemented sedation protocol on the duration of
mechanical ventilation. Crit Care Med. 1999;27:2609–15.
12. Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP. Daily
interruption of sedative infusions and complications of critical illness in
mechanically ventilated patients. Crit Care Med. 2004;32:1272–6.
13. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, et al.
Efficacy and safety of a paired sedation and ventilator weaning protocol for
mechanically ventilated patients in intensive care (Awakening and
Breathing Controlled trial): a randomised controlled trial. Lancet.
2008;371:126–34.
14. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative
infusions in critically ill patients undergoing mechanical ventilation. N Engl J
Med. 2000;342:1471–7.
15. Ali NA. Have we found the prevention for intensive care unit-acquired
paresis? Crit Care. 2010;14:160.
16. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL,
et al. Early physical and occupational therapy in mechanically ventilated,
critically ill patients: a randomised controlled trial. Lancet. 2009;373:1874–82.
17. Kress JP. Clinical trials of early mobilization of critically ill patients. Crit Care
Med. 2009;37:S442–7.
18. Kress JP. Sedation and mobility: changing the paradigm. Crit Care Clin.
2013;29:67–75.
19. Lipshutz AK, Gropper MA. Acquired neuromuscular weakness and early
mobilization in the intensive care unit. Anesthesiology. 2013;118:202–15.
20. de Jonghe B, Lacherade JC, Sharshar T, Outin H. Intensive care unit-acquired
weakness: risk factors and prevention. Crit Care Med. 2009;37:S309–15.
21. Hermans G, Schrooten M, Van Damme P, Berends N, Bouckaert B, De
Vooght W, et al. Benefits of intensive insulin therapy on neuromuscular
complications in routine daily critical care practice: a retrospective study.
Crit Care. 2009;13:R5.
22. Chrispin PS, Scotton H, Rogers J, Lloyd D, Ridley SA. Short Form 36 in the
intensive care unit: assessment of acceptability, reliability and validity of the
questionnaire. Anaesthesia. 1997;52:15–23.
23. Ware J, Kosinski M. SF-36 physical and mental health summary scales: a
manual for users of version 1. 2nd ed. Lincoln, RI: QualityMetric
Incorporated; 2001.
24. Collin C, Wade D, Davies S, Horne V. The Barthel ADL Index: a reliability
study. Int Disabil Stud. 1988;10:61–3.
25. Wade D, Collin C. The Barthel ADL Index: a standard measure of physical
disability? Int Disabil Stud. 1988;10:64–7.
26. Mahoney F, Barthel D. Functional evaluation: the Barthel Index. Md State
Med J. 1965;14:61–5.
27. Rikli R, Jones C. Development and validation of criterion-referenced clinically
relevant fitness standards for maintaining physical independence in later
years. Gerontologist. 2013;53:255–67.
28. Applegate W, Blass J, Williams T. Instruments for the functional assessment
of older patients. N Engl J Med. 1990;26:1207–14.29. Elliott D, Denehy L, Berney S, Alison JA. Assessing physical function and
activity for survivors of a critical illness: a review of instruments. Aust Crit
Care. 2011;24:155–66.
30. Crapo RO, Casaburi R, Coates AL, Enright PL, MacIntyre NR, McKay RT, et al.
American Thoracic Society ATS statement: guidelines for the six-minute
walk test. Am J Respir Crit Care Med. 2002;166:111–7.
31. Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP, et al. The 6-min
walk distance in healthy subjects: reference standards from seven countries.
Eur Respir J. 2010;37:150–6.
32. Wise RA, Brown CD. Minimal clinically important differences in the six-
minute walk test and the incremental shuttle walking test. J Chron Obstruct
Pulmon Dis. 2005;2:125–9.
33. Massy-Westropp N, Rankin W, Ahern M, Krishnan J, Hearn TC. Measuring
grip strength in normal adults: reference ranges and a comparison of
electronic and hydraulic instruments. J Hand Surg [Am]. 2004;29:514–9.
34. Fairfax AH, Balnave R, Adams RD. Variability of grip strength during
isometric contraction. Ergonomics. 1995;38:1819–30.
35. Lee YD. Can hand dynamometry serve as a simple test to identify ICU-acquired
paresis? Am J Respir Crit Care Med. 2009;179:329–30.
36. Gruther W, Benesch T, Zorn C, Paternostro-Sluga T, Quittan M, Fialka-Moser
V, et al. Muscle wasting in intensive care patients: ultrasound observation of
the M. quadriceps femoris muscle layer. J Rehabil Med. 2008;40:185–9.
37. Andersen LL, Holtermann A, Jørgensen MB, Sjøgaard G. Rapid muscle
activation and force capacity in conditions of chronic musculoskeletal pain.
Clin Biomech. 2008;23:1237–42.
38. Andersen LL, Andersen JL, Suetta C, Kjaer M, Søgaard K, Sjøgaard G. Effect
of contrasting physical exercise interventions on rapid force capacity of
chronically painful muscles. J Appl Physiol. 2009;107:1413–9.
39. Faber A, Hansen K, Christensen H. Muscle strength and aerobic capacity in a
representative sample of employees with and without repetitive
monotonous work. Int Arch Occup Environ Health. 2006;79:33–41.
40. Sjøgaard G, Søgaard K, Hermens HJ, Sandsjö L, Läubli T, Thorn S, et al.
Neuromuscular assessment in elderly workers with and without work
related shoulder/neck trouble: the NEW-study design and physiological
findings. Eur J Appl Physiol. 2006;96:110–21.
41. Dupont WD, Plummer WD. Power and sample size calculations. A review
and computer program. Control Clin Trials. 1990;11:116–28.
42. Afshari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill
patients: systematic review with meta-analysis and trial sequential analysis.
BMJ. 2007;335:1248–51.
43. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A,
et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis.
N Engl J Med. 2012;367:124–34.
44. Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day AG. A long-term
follow-up study investigating health-related quality of life and resource use in
survivors of severe sepsis: comparison of recombinant human activated protein C
with standard care. Crit Care. 2007;11:R128.
45. Ryan T, Enderby P, Rigby A. A randomized controlled trial to evaluate
intensity of community-based rehabilitation provision following stroke or
hip fracture in old age. Clin Rehabil. 2006;20:123–31.
46. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8:3–15.
47. Poulsen JB, Rose MH, Jensen BR, Møller K, Perner A. Biomechanical and
nonfunctional assessment of physical capacity in male ICU survivors. Crit
Care Med. 2013;41:93–101.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
